New Alzheimer's drug AK152 enters first human safety trial
NCT ID NCT07301502
First seen Jan 07, 2026 · Last updated May 24, 2026 · Updated 23 times
Summary
This early-stage study tests the safety and tolerability of a new drug called AK152 in healthy volunteers and people with Alzheimer's disease. The trial will also measure how the drug moves through the body and whether it triggers an immune response. About 108 participants will take part, and the goal is to gather initial safety data before larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Frist Affiliated Hospital of USTC
Hefei, Anhui, China
Conditions
Explore the condition pages connected to this study.